Terapi Pada Pasien COVID-19 derajat berat/kritis Di Salah Satu Rumah Sakit Yogyakarta
Farisa Luthfiana(1*), Agung Endro Nugroho(2), Ika Puspitasari(3)
(1) Gadjah Mada University
(2) Fakultas Farmasi Universitas Gadjah Mada
(3) Fakultas Farmasi Universitas Gadjah Mada
(*) Corresponding Author
Abstract
Pasien gejala ringan sampai sedang banyak mengalami perbaikan setelah mendapatkan pengobatan, akan tetapi pada pasien gejala berat/kritis di ICU memiliki mortalitas yang lebih tinggi walaupun telah mendapatkan terapi. Terapi yang ditemukan dilapangan masih sangat beragam. Penelitian ini bertujuan untuk mengetahui pola pengobatan pasien COVID-19 gejala berat/kritis di salah satu rumah sakit Yogyakarta Penelitian ini merupakan penelitian deskriptif dalam bentuk case series pada 10 pasien COVID-19 gejala berat/kritis yang membaik dan 10 pasien COVID-19 gejala berat/kritis yang meninggal, data diambil secara retrospektif melalui rekam medik pasien COVID-19 rawat inap pada periode 1 Januari -31 Juli 2021. Analisis data dilakukan dengan cara deskriptif dalam bentuk rata-rata/persentase untuk mendapatkan gambaran pola penggunaan obat. Penelitian ini diharapkan menjadi sarana pembelajaran bagi praktisi dan referensi dalam penelitian selanjutnya mengenai pola penggunaan obat pasien COVID-19 gejala berat/kritis. Kelompok pasien meninggal 100 % menggunakan antivirus, 100 % menggunakan antibiotik, 90% menggunakan antiinflamasi, 80% antikoagulan dan terapi tambahan ( 60 % N-Acetyl Cysteine (NAC), 10% kolkisin). Kelompok pasien membaik 100 % menggunakan antivirus, 100% menggunakan antibiotik, 80 % menggunakan antiinflamasi, 90% menggunakan antikoagulan, terapi tambahan (90% NAC, 30% kolkisin). Antibiotik dan antivirus merupakan golongan obat yang banyak digunakan pada kedua kelompok dan kelompok pasien membaik dan kelompok pasien membaik mendapatkan terapi tambahan (NAC dan Kolkisin) lebih banyak dibanding kelompok meninggal, sehingga diperlukan penelitian lebih lanjut mengenai manfaat dari terapi tambahan pada pasien COVID-19 berat/kritis.
Keywords
Full Text:
PDFReferences
Annane, D., 2021. Corticosteroids for COVID-19. J. Intensive Med. 1: 14–25. Archived: WHO Timeline - COVID-19 (2020) 27 April 2020. Tersedia pada: https://www.who.int/news-room/detail/27-04-2020-who-timeline---covid-19 (Diakses: 26 Agustus 2020). Belančić, A., Kresović, A., and Rački, V., 2020. Potential pathophysiological mechanisms leading to increased COVID-19 susceptibility and severity in obesity. Obes. Med. 19: 100259. Bleyzac, N., Goutelle, S., Bourguignon, L., and Tod, M., 2020. Azithromycin for COVID-19: More Than Just an Antimicrobial?, Clin. Drug Investig. 40: 683–686. Chen, Y., Zhang, K., Zhu, G., Liu, L., et al. 2020. Clinical characteristics and treatment of critically ill patients with COVID-19 in Hebei. Ann. Cardiothorac. Surg. 9: 2118–2130. Huttner, B.D., Catho, G., Pano-Pardo, J.R., Pulcini, C., Schouten, J., 2020. COVID-19: don’t neglect antimicrobial stewardship principles!, Clin. Microbiol. Infect. 26: 808. Ikatan Dokter Indonesia, 2020. Rekomendasi IDI, Pemberian Antikoagulan Profilaksis Pada Pasien Covid-19 yang Dirawat di Rumah Sakit. Ikat. Dr. Indones. 4: 57–71. Leoni, M.L.G., Lombardelli, L., Colombi, D., Bignami, E.G., Pergolotti, B., Repetti, F., et al., 2021. Prediction of 28-day mortality in critically ill patients with COVID-19: Development and internal validation of a clinical prediction model. PLoS One. 16: 1-13 Lopes, Maria Isabela, et. al, 2021. Beneficial effects of colchicine for moderate to sever COVID-19 : a randomised, double-blinded, placebo-controlled clinical trial.RMD open. 7: 2-8 Maskin, L.P., Olarte, G.L., Palizas, F., Velo, A.E., Lurbet, M.F., Bonelli, I., Baredes, N.D., Rodríguez, P.O., 2020. High dose dexamethasone treatment for Acute Respiratory Distress Syndrome secondary to COVID-19: A structured summary of a study protocol for a randomised controlled trial. BMC. 21:1-3 Mazzuchelli, T., Lo Priore, E., Balmelli, C., Llamas, M., Pallanza, M., Elzi, L., et al., 2020. Early administered antibiotics do not impact mortality in critically ill patients with COVID-19. J. Infect. 81: e148–e149 PDPI, PERKI, PAPDI, PERDATIN, IDAI, 2020. Pedoman tatalaksana COVID-19 Edisi 3 Desember 2020, Pedoman Tatalaksana COVID-19.1-149 PDPI, et al., 2021. Revisi Protokol Tatalaksana COVID-19. PDPI. 1-50 Peta Sebaran COVID-19 | Covid19.go.id (tanpa tanggal) 2021. Tersedia pada: https://covid19.go.id/peta-sebaran-covid19 (Diakses: 12 Oktober 2021). Ramanathan, K., Antognini, D., Combes, A., Paden, M., Zakhary, B., Ogino, M.,et al., 2020. Azithromycin in addition to standard of care versus standard of care alone in the treatment of patients admitted to the hospital with severe COVID-19 in Brazil (COALITION II): a randomised clinical trial, Lancet. 396: 959-967 Rochwerg, B., Agarwal, A., Siemieniuk, R.A., Agoritsas, T., Lamontagne, F., Askie, et al., 2020. A living WHO guideline on drugs for covid-19. BMJ. 370:1-13 Shah, H., Khan, M.S.H., Dhurandhar, N. V., and Hegde, V., 2021. The triumvirate: why hypertension, obesity, and diabetes are risk factors for adverse effects in patients with COVID-19. Acta Diabetol. 58: 831–843. Touret, F., Gilles, M., Barral, K., Nougairède, A., van Helden, J., Decroly, E., et al., 2020. In vitro screening of a FDA approved chemical library reveals potential inhibitors of SARS-CoV-2 replication. Sci. Rep.10: 1-9 Vecchié, A., Batticciotto, A., Tangianu, F., Bonaventura, A., Pennella, B., Abenante, et al., 2021. High-dose dexamethasone treatment for COVID-19 severe acute respiratory distress syndrome: a retrospective study. Intern. Emerg. Med. 1-7 Watson, J., Jones, H.E., Banks, J., Whiting, P., Salisbury, C., and Hamilton, W., 2019. Use of multiple inflammatory marker tests in primary care: Using Clinical Practice Research Datalink to evaluate accuracy. Br. J. Gen. Pract. 69:E662-E669 Xu, W., Sun, N.N., Gao, H.N., Chen, Z.Y., Yang, Y., Ju, B., and Tang, L.L., 2021. Risk factors analysis of COVID-19 patients with ARDS and prediction based on machine learning. Sci. Rep. 11: 1–12. Zhong, Z., Li, H., Zhu, J., Ji, P., Li, B., Pang, J., Zhang, J., and Liang, X., 2021. Clinical characteristics of 2,459 severe or critically ill COVID-19 patients: A meta-analysis. Medicine (Baltimore). 100: e23781.
DOI: https://doi.org/10.22146/farmaseutik.v19i1.70344
Article Metrics
Abstract views : 674 | views : 306Refbacks
- There are currently no refbacks.